Skip to content
naulon

Not checkedNot checked for notices yet.

Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

Maria L. Lozano, Maria E. Mingot-Castellano, María M. Perera and 18 more

Scientific Reports · 2021

doi:10.1038/s41598-021-95732-x (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The original version of this Article contained errors in Figures 1 and 2 . Figure 1 Probability of maintaining therapy free responses (TFR) upon TPO-RA discontinuation. Kaplan–Meier plot showing the estimated probability of TFR in patients who discontinue TPO-RA for reasons other than lack of efficacy and being followed for a minimum of 6 months (n = 41). Patients who died while on TPO-RA therapy were not included in the study. Solid black line represents patients that received only romiplostim (n = 23); solid grey line represents patients that received only eltrombopag (n = 12), and dashed black line represents patients that switched TPO-RA (n = 6). The number of patients that discontinue TPO therapy (“at risk”) and the cumulative loss of TFR events at time points are presented for each group below the figure. Full size image Figure 2 Probability of achieving therapy free responses (TFR). Proportion of patients achieving TFR within the whole cohort (n = 121) included in the study (panel a ), and in those with chronic ITP (panel b ). TFR was defined as the ability of a patient to discontinue TPO-RA as platelet counts > 50 × 10 9 /l for at least 6 months in the absence of any therapies meant to increase platelet counts. Patients who died while on TPO-RA therapy were not included in the study. Solid black line represents patients that received only romiplostim (Panel a , n = 41; Panel b , n = 29). Solid grey line represents patients that received only eltrombopag (Panel a , n = 41; Panel b , n = 24). Dashed black line represents patients that initiated romiplostim and switched to eltrombopag (Panel a , n = 13; Panel b , n = 8). Dashed grey line represents patients that initiated eltrombopag and switched to romiplostim (Panel a , n = 26; Panel b , n = 21). The number of patients under TPO therapy (“at risk”) and the cumulative TFR at time points are presented for each group below each figure. Full size image

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.